Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

AIMS: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme. MATERIALS AND METHODS: The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon‐like peptide‐1 analogue, for the treatment of type 2 diabetes (T2D). In SUSTAIN...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilsbøll, Tina, Bain, Stephen C., Leiter, Lawrence A., Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888154/
https://www.ncbi.nlm.nih.gov/pubmed/29178519
http://dx.doi.org/10.1111/dom.13172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888154/
https://www.ncbi.nlm.nih.gov/pubmed/29178519
http://dx.doi.org/10.1111/dom.13172

Ejemplares similares